Long-term cost effectiveness of drotrecogin alfa (activated): an unanswered question.
Banks
Steven M
SM
Gerstenberger
Eric
E
Eichacker
Peter Q
PQ
Natanson
Charles
C
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000890:Anti-Infective Agents / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D017048:Health Care Costs; D006801:Humans; D008875:Middle Aged; D011486:Protein C / Q000191:economics* / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000191:economics* / Q000627:therapeutic use; D018805:Sepsis / Q000188:drug therapy* / Q000401:mortality; D016019:Survival Analysis; D014481:United States
D000890:Anti-Infective Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated